Compare ASH & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASH | GPCR |
|---|---|---|
| Founded | 1924 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2016 | 2023 |
| Metric | ASH | GPCR |
|---|---|---|
| Price | $57.23 | $37.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $65.57 | ★ $103.17 |
| AVG Volume (30 Days) | 772.3K | ★ 815.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,824,000,000.00 | N/A |
| Revenue This Year | $2.58 | N/A |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $681.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.30 | $15.80 |
| 52 Week High | $65.65 | $94.90 |
| Indicator | ASH | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 25.70 |
| Support Level | $53.89 | $30.82 |
| Resistance Level | $60.79 | $40.29 |
| Average True Range (ATR) | 2.42 | 2.40 |
| MACD | 0.18 | -0.32 |
| Stochastic Oscillator | 89.47 | 3.96 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.